Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flufenamic acid
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Flufenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) of the anthranilic acid derivative (fenamate) class. It acts primarily as an inhibitor of prostaglandin-endoperoxide synthase (cyclooxygenase or COX), thereby reducing prostaglandin synthesis and exerting analgesic, anti-inflammatory, and antipyretic effects[1][2][3][4][5]. Flufenamic acid also modulates various ion channels including non-selective cation channels and chloride channels[5][6]. It has been used to treat pain associated with rheumatic diseases such as rheumatoid arthritis and osteoarthritis but is less commonly used today due to a high incidence of gastrointestinal side effects[3]. The drug is administered orally or topically for musculoskeletal and joint disorders[2][4]. **Developers:** Parke-Davis
- Brand names
- ArlefAchlessFullsafeSurika
- Other names
- FFAN-(alpha,alpha,alpha-trifluoro-m-tolyl) anthranilic acidflufenamate
02
Targets
AKR1B10 (Aldo-keto reductase family 1 member B10)ClC (CLC chloride channel family)PGHS-1 (Prostaglandin G/H Synthase 1)AKR1B1 (Aldose Reductase)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPC6 (Transient receptor potential canonical type 6)TRPM4 (Calcium-activated non-selective cation channel TRPM4)
Beyond the preview
Go deeper on Flufenamic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flufenamic acid.